Announcement of the Resolution of Annual General
Meeting to Approve of Lifting of Non-Competition
Restrictions for Board Director.
Date of events
2022/06/17
To which item it meets
paragraph 21
Statement
1.Date of the shareholders meeting resolution:2022/06/17
2.Name and title of the director with permission to engage in competitive
conduct:
Yen, Yun/Director
Chen, Chi-Chuan/Director
Tseng, Tamon/Director
Allen Chao/Director
David Hsia/Director
Xue, Ula/Director
Tsai, Jin-Pau/Independent Director
Wang, Tay-hang/Independent Director
3.Items of competitive conduct in which the director is permitted to engage:
To engage in business that are identical or similar to the business scope of
Tanvex
4.Period of permission to engage in the competitive conduct:
During the period of employment as independent directors of the company.
5.Circumstances of the resolution (please describe the results of voting in
accordance with Article 209 of the Company Act):
The votes in favor of the total represented share is 85.11%, and hereby
was approved as proposed.
6.If the permitted competitive conduct belongs to the operator of a mainland
China area enterprise, the name and title of the directors
(if it is not the operator of a Mainland-area enterprise, please enter
"N/A" below):N/A
7.Company name of the mainland China area enterprise and the director's
position in the enterprise:N/A
8.Address of the mainland China area enterprise:N/A
9.Operations of the mainland China area enterprise:N/A
10.Impact on the company's finance and business:None
11.If the directors have invested in the mainland China area enterprise,
the monetary amount of the investment and their shareholding ratio:N/A
12.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
Tanvex Biopharma Inc. published this content on 17 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 June 2022 11:52:06 UTC.
Tanvex BioPharma, Inc. is a Cayman Islands-based biopharmaceutical company focused on the biosimilar market. The company has expertise in areas, including strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and others. The Companyâs product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), Perjeta (TX-52), and others. The Company offers a vertically integrated manufacturing platform for biopharmaceuticals. The Company is developing and delivering biologic and biosimilar drugs to people.
TANVEX BIOPHARMA, INC. 
